Duyuru • Jul 07
CMG Pharmaceutical Co., Ltd. announced that it has received KRW 45 billion in funding from Korea Investment & Securities Co., Ltd. On July 7, 2026, CMG Pharmaceutical Co., Ltd. closed the offering. New Risk • Jun 08
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: ₩154.5b (US$99.0m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 84% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩154.5b market cap, or US$99.0m). Duyuru • Mar 13
CMG Pharmaceutical Co., Ltd., Annual General Meeting, Mar 27, 2026 CMG Pharmaceutical Co., Ltd., Annual General Meeting, Mar 27, 2026, at 09:01 Tokyo Standard Time. Location: auditorium, 248, seohaean-ro, gyeonggi-do, siheung South Korea Reported Earnings • Nov 19
Third quarter 2025 earnings released: EPS: ₩39.00 (vs ₩19.00 loss in 3Q 2024) Third quarter 2025 results: EPS: ₩39.00 (up from ₩19.00 loss in 3Q 2024). Revenue: ₩30.4b (up 23% from 3Q 2024). Net income: ₩5.73b (up ₩8.41b from 3Q 2024). Profit margin: 19% (up from net loss in 3Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 78 percentage points per year, which is a significant difference in performance. New Risk • Aug 30
New major risk - Financial data availability The company's latest financial reports are more than a year old. Last reported fiscal period ended September 2013. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported September 2013 fiscal period end). High level of non-cash earnings (64% accrual ratio). New Risk • May 23
New major risk - Revenue and earnings growth Earnings have declined by 1.2% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 1.2% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (12% average weekly change). New Risk • Apr 16
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (2.7% net profit margin). New Risk • Mar 28
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 2.7% Last year net profit margin: 6.9% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (2.7% net profit margin). Duyuru • Mar 13
CMG Pharmaceutical Co., Ltd., Annual General Meeting, Mar 28, 2025 CMG Pharmaceutical Co., Ltd., Annual General Meeting, Mar 28, 2025, at 09:01 Tokyo Standard Time. Location: conference room, 248, seohaean-ro, gyeonggi-do, siheung South Korea New Risk • Dec 16
New major risk - Financial data availability The company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. This is currently the only risk that has been identified for the company. New Risk • Dec 09
New major risk - Financial data availability The company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. This is currently the only risk that has been identified for the company. Reported Earnings • Nov 15
Third quarter 2024 earnings released: ₩19.00 loss per share (vs ₩19.00 profit in 3Q 2023) Third quarter 2024 results: ₩19.00 loss per share (down from ₩19.00 profit in 3Q 2023). Revenue: ₩24.7b (up 5.0% from 3Q 2023). Net loss: ₩2.68b (down 199% from profit in 3Q 2023). New Risk • Sep 17
New major risk - Financial data availability The company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. This is currently the only risk that has been identified for the company. New Risk • Aug 17
New major risk - Earnings quality The company has a high level of non-cash earnings. Accrual ratio: 20% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. This is currently the only risk that has been identified for the company. Reported Earnings • Aug 17
Second quarter 2024 earnings released: EPS: ₩43.00 (vs ₩27.00 in 2Q 2023) Second quarter 2024 results: EPS: ₩43.00 (up from ₩27.00 in 2Q 2023). Revenue: ₩24.9b (down 2.3% from 2Q 2023). Net income: ₩5.98b (up 62% from 2Q 2023). Profit margin: 24% (up from 14% in 2Q 2023). Valuation Update With 7 Day Price Move • Aug 05
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to ₩2,000, the stock trades at a trailing P/E ratio of 46.3x. Average trailing P/E is 14x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 59% over the past three years. Board Change • Nov 16
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Board Change • Apr 27
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Is New 90 Day High Low • Feb 24
New 90-day low: ₩4,400 The company is down 5.0% from its price of ₩4,630 on 26 November 2020. The South Korean market is up 17% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 6.0% over the same period. Is New 90 Day High Low • Dec 18
New 90-day high: ₩6,350 The company is up 38% from its price of ₩4,605 on 18 September 2020. The South Korean market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 5.0% over the same period. Is New 90 Day High Low • Dec 02
New 90-day high: ₩5,050 The company is up 11% from its price of ₩4,540 on 03 September 2020. The South Korean market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 1.0% over the same period. Is New 90 Day High Low • Oct 29
New 90-day high: ₩4,900 The company is up 13% from its price of ₩4,355 on 31 July 2020. The South Korean market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 1.0% over the same period. 
